Transactivation response DNA‐binding protein of 43 kDa proteinopathy and lysosomal abnormalities in spastic paraplegia type 11
Neuropathology · 2021-08 · 41 (4) · 253-265
DOI: 10.1111/neup.12733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropathology, online erschienen am 24.05.2021. Verfasst von Shinichiro Mori und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Spastic Paraplegia, Hereditary. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Spastic paraplegia type 11 (SPG11) is the most common autosomal recessive hereditary spastic paraplegia with thinning of the corpus callosum. Spatacsin, a protein encoded by the SPG11 gene, is associated with autophagy. SPG11 patients show spastic paraplegia, intellectual disability, dementia, and parkinsonism. A previous neuropathological analysis of SPG11 cases reported neurodegeneration mimicking amyotrophic lateral sclerosis without transactivation response DNA‐binding protein of 43 kDa (TDP‐43) deposits and unique sequestosome 1 (SQSTM1)‐positive neuronal inclusions. We performed a neuropathological examination of two Japanese patients with complicated spastic paraplegia with thinning of the corpus callosum from different families, and one was genetically diagnosed as having SPG11. Both cases showed diffuse atrophy of the brain and spinal cord. Depigmentation of the substantia nigra was also observed. Immunohistochemistry revealed widespread distribution of areas showing TDP‐43 aggregation in the central nervous system. The TDP‐43 deposits in the thalamus and substantia nigra especially resembled skein‐like inclusions. Unique SQSTM1‐positive neuronal inclusions, as previously reported, were widespread in the whole central nervous system as well as the dorsal root ganglia. Double‐labeling immunofluorescence of the dorsal root ganglia revealed that the unique, large SQSTM1‐positive cytoplasmic inclusions of the ganglion cells were labeled with lysosome‐associated membrane protein 1 and lysosome‐associated membrane protein 2. This is the first report showing TDP‐43 pathology in SPG11. The common neuropathological findings of TDP‐43–positive inclusions in both the cases imply a causal connection between the TDP‐43 proteinopathy and autophagy dysfunction in SPG11.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Neurology, Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Neurology, Neuro-Muscular Center, National Omuta Hospital, Omuta, Japan.
- Department of Neurology, Kochi Medical School, Kochi University, Nankoku, Japan.
ORCID-Profile: Shinichiro Mori, Hiroyuki Honda, Toru Iwaki
Zitieren
APA
Mori, S., Honda, H., Hamasaki, H., Sasagasako, N., Suzuki, S. O., Furuya, H., Taniwaki, T., & Iwaki, T. (2021). Transactivation response DNA‐binding protein of 43 kDa proteinopathy and lysosomal abnormalities in spastic paraplegia type 11. Neuropathology, 41(4), 253-265. https://doi.org/10.1111/neup.12733
Vancouver
Mori S, Honda H, Hamasaki H, Sasagasako N, Suzuki SO, Furuya H, et al. Transactivation response DNA‐binding protein of 43 kDa proteinopathy and lysosomal abnormalities in spastic paraplegia type 11. Neuropathology. 2021;41(4):253-265. doi:10.1111/neup.12733
BibTeX
@article{Mori2021,
author = {Mori, Shinichiro and Honda, Hiroyuki and Hamasaki, Hideomi and Sasagasako, Naokazu and Suzuki, Satoshi O and Furuya, Hirokazu and Taniwaki, Takayuki and Iwaki, Toru},
title = {Transactivation response DNA‐binding protein of 43 kDa proteinopathy and lysosomal abnormalities in spastic paraplegia type 11},
journal = {Neuropathology},
year = {2021},
volume = {41},
number = {4},
pages = {253--265},
doi = {10.1111/neup.12733}
}
EUVIMED